Hunt BioVentures makes investments in young private and public companies with a focus on pharmaceuticals, medical devices and agricultural biotech opportunities. With a start in 2001, Hunt has continually pursued companies with clinical efficacy data or strong human proxy data, which has typically meant companies with products in various stages of clinical trials. Although this later-stage approach will always be core to Hunt’s investment strategy, Hunt will occasionally pursue pre-clinical opportunities, especially those with exceptional management teams. Another important component of the strategy is to invest alongside other experienced life science investors in either a “co-lead” or “follower” manner.
Focus Areas
Investment Types
Notable Investments
